Discovery to Diagnostics Whitepaper Part 3
Neurological disorders have long posed challenges for research, leaving patients with limited treatment options. However, recent breakthroughs in disease-modifying therapies offer hope to those suffering from progressive neuropathies. Despite these advancements, transitioning therapeutic agents from research to clinical settings is a meticulous process requiring close collaboration between researchers, clinicians, and patients.
Early-stage asymptomatic patients have the highest chance of benefiting from new treatments. Thus, identifying and recruiting these patients for clinical trials is highly important. However, a lack of early and sensitive screening tools complicates early disease detection and patient inclusion in cohort studies. Fortunately, blood-based biomarkers have emerged as a powerful tool for early patient identification and therapeutic response monitoring4. The ability to measure blood-based biomarkers associated with disease pathology in blood samples represents a pivotal moment for neurological drug development. The adoption hopes to usher in significant enhancements to clinical trial execution, facilitating recruitment processes, decreasing time and expenses, and ultimately increasing the likelihood of effective treatments. Download our whitepaper to learn more.
Related Posts
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…
Neurology
Expanding Access to Ultra-Sensitive Biomarker Testing: Urine as a Non-Invasive Matrix for Simoa Assays
Urine as a Non-Invasive Matrix for Ultra-Sensitive Biomarker Detection with Simoa® The Simoa® platform extends its unmatched sensitivity to urine, enabling detection of low-abundance neurological and infectious disease biomarkers in…